Nutriband and Kindeva Drug Delivery Formalize Exclusive Development Partnership for Aversa™ Fentanyl Abuse Deterrent Fentanyl Patch
Nutriband Inc. (NASDAQ:NTRB) has formalized an exclusive development partnership with Kindeva Drug Delivery for Aversa™ Fentanyl, an abuse-deterrent fentanyl patch. The partnership involves shared development costs in exchange for milestone payments. The product combines Nutriband's Aversa™ abuse-deterrent technology with Kindeva's FDA-approved fentanyl patch.
The Aversa™ technology incorporates aversive agents into transdermal patches to prevent abuse, diversion, misuse, and accidental exposure of drugs with abuse potential. The technology is protected by patents in 46 countries, including major markets like the US, Europe, Japan, and China. If successful, Aversa Fentanyl would become the world's first abuse-deterrent opioid patch, with potential peak annual US sales ranging from $80 million to $200 million.
Nutriband Inc. (NASDAQ:NTRB) ha formalizzato una partnership di sviluppo esclusiva con Kindeva Drug Delivery per Aversa™ Fentanyl, un cerotto al fentanyl progettato per prevenire l'abuso. La partnership prevede la condivisione dei costi di sviluppo in cambio di pagamenti legati a traguardi. Il prodotto combina la tecnologia anti-abuso Aversa™ di Nutriband con il cerotto al fentanyl approvato dalla FDA di Kindeva.
La tecnologia Aversa™ incorpora agenti aversivi nei cerotti transdermici per prevenire l'abuso, la deviazione, l'uso improprio e l'esposizione accidentale a farmaci con potenziale di abuso. La tecnologia è protetta da brevetti in 46 paesi, inclusi i principali mercati come Stati Uniti, Europa, Giappone e Cina. Se avrà successo, Aversa Fentanyl diventerebbe il primo cerotto oppioide anti-abuso al mondo, con vendite annuali potenziali negli Stati Uniti che potrebbero variare da 80 milioni a 200 milioni di dollari.
Nutriband Inc. (NASDAQ:NTRB) ha formalizado una asociación de desarrollo exclusiva con Kindeva Drug Delivery para Aversa™ Fentanyl, un parche de fentanilo diseñado para prevenir el abuso. La asociación implica compartir los costos de desarrollo a cambio de pagos por hitos. El producto combina la tecnología de prevención de abuso Aversa™ de Nutriband con el parche de fentanilo aprobado por la FDA de Kindeva.
La tecnología Aversa™ incorpora agentes aversivos en parches transdérmicos para prevenir el abuso, la desviación, el uso indebido y la exposición accidental a medicamentos con potencial de abuso. La tecnología está protegida por patentes en 46 países, incluidos mercados importantes como EE. UU., Europa, Japón y China. Si tiene éxito, Aversa Fentanyl se convertiría en el primer parche de opioides con prevención de abuso en el mundo, con ventas anuales potenciales en EE. UU. que oscilarían entre 80 millones y 200 millones de dólares.
Nutriband Inc. (NASDAQ:NTRB)는 Kindeva Drug Delivery와 함께 남용 방지 파트너십을 공식화했습니다. Aversa™ Fentanyl은 남용 방지 기능이 있는 펜타닐 패치입니다. 이 파트너십은 이정표에 따른 지급금을 대가로 개발 비용을 공유하는 내용을 포함합니다. 이 제품은 Nutriband의 Aversa™ 남용 방지 기술과 Kindeva의 FDA 승인 펜타닐 패치를 결합한 것입니다.
Aversa™ 기술은 남용, 전용, 오용 및 약물의 우발적인 노출을 방지하기 위해 전이성 패치에 혐오 물질을 통합합니다. 이 기술은 미국, 유럽, 일본, 중국과 같은 주요 시장을 포함하여 46개국에서 특허로 보호받고 있습니다. 성공할 경우, Aversa Fentanyl은 세계 최초의 남용 방지 오피오이드 패치가 될 것이며, 미국에서의 연간 최대 판매액은 8천만 달러에서 2억 달러에 이를 것으로 예상됩니다.
Nutriband Inc. (NASDAQ:NTRB) a formalisé un partenariat de développement exclusif avec Kindeva Drug Delivery pour Aversa™ Fentanyl, un patch de fentanil conçu pour prévenir l'abus. Le partenariat implique le partage des coûts de développement en échange de paiements liés à des jalons. Le produit combine la technologie de prévention de l'abus Aversa™ de Nutriband avec le patch de fentanil approuvé par la FDA de Kindeva.
La technologie Aversa™ intègre des agents aversifs dans des patchs transdermiques pour prévenir l'abus, la déviation, l'usage inapproprié et l'exposition accidentelle à des médicaments potentiellement abusifs. La technologie est protégée par des brevets dans 46 pays, y compris des marchés majeurs comme les États-Unis, l'Europe, le Japon et la Chine. Si elle réussit, Aversa Fentanyl deviendrait le premier patch opioïde anti-abus au monde, avec des ventes annuelles potentielles aux États-Unis allant de 80 millions à 200 millions de dollars.
Nutriband Inc. (NASDAQ:NTRB) hat eine exklusive Entwicklungspartnerschaft mit Kindeva Drug Delivery für Aversa™ Fentanyl, ein Missbrauch verhinderndes Fentanyl-Pflaster, formalisiert. Die Partnerschaft umfasst die gemeinsamen Entwicklungskosten im Austausch gegen Meilensteinzahlungen. Das Produkt kombiniert die missbrauchsverhindernde Technologie Aversa™ von Nutriband mit dem von der FDA genehmigten Fentanyl-Pflaster von Kindeva.
Die Aversa™-Technologie integriert aversive Substanzen in transdermale Pflaster, um Missbrauch, Abweichung, Fehlgebrauch und versehentliche Exposition gegenüber Drogen mit Missbrauchspotenzial zu verhindern. Die Technologie ist in 46 Ländern durch Patente geschützt, darunter wichtige Märkte wie die USA, Europa, Japan und China. Im Erfolgsfall würde Aversa Fentanyl das weltweit erste missbrauchsverhindernde Opioid-Pflaster werden, mit potenziellen jährlichen Verkaufszahlen in den USA, die zwischen 80 Millionen und 200 Millionen Dollar liegen.
- Exclusive development partnership secured with established CDMO Kindeva Drug Delivery
- Broad international patent protection across 46 countries
- Potential peak annual US sales of $80-200 million
- First-mover advantage in abuse-deterrent opioid patch market
- Development costs will be shared, increasing financial burden
- Product still in development phase with no guaranteed success
Insights
The formalization of Nutriband's partnership with Kindeva Drug Delivery represents a pivotal development in addressing one of healthcare's most pressing challenges - opioid abuse prevention. The Aversa™ technology's unique approach using taste aversion demonstrates significant innovation in the $4.3 billion transdermal drug delivery market.
Several key factors make this partnership particularly noteworthy:
- The cost-sharing development model significantly reduces Nutriband's financial burden while maintaining substantial upside through milestone payments, important for a company with a market cap of
$74.5 million - The extensive patent protection across 46 countries creates a robust barrier to entry and positions Aversa™ Fentanyl for global commercialization
- Kindeva's expertise in FDA-approved fentanyl patches substantially de-risks the development process
The projected peak annual US sales of
The partnership's structure, combining shared development costs with milestone payments, suggests careful cash flow management while maintaining Nutriband's upside potential. This arrangement is particularly advantageous for Nutriband, allowing it to leverage Kindeva's extensive development and manufacturing expertise while preserving significant economic interest in the product's success.
Nutriband and Kindeva formalize exclusive product development partnership and long-term commitment based on shared development costs in exchange for milestone payments
Nutriband is partnering with Kindeva Drug Delivery to develop Aversa™ Fentanyl which combines Nutriband’s Aversa™ abuse-deterrent technology with Kindeva’s FDA-approved fentanyl patch.
ORLANDO, Fla., Feb. 13, 2025 (GLOBE NEWSWIRE) -- Nutriband Inc. (NASDAQ:NTRB)(NASDAQ:NTRBW), a company engaged in the development of prescription transdermal pharmaceutical products, today announced that it has signed an addendum to the Commercial Development and Clinical Supply Agreement for its lead product, Aversa™ Fentanyl, that it has in place with its partner, Kindeva Drug Delivery, a leading global contract development and manufacturing organization (CDMO) focused on drug-device combination products.
Nutriband and Kindeva have revised their agreement to formalize their exclusive product development partnership and long-term commitment based on shared development costs in exchange for milestone payments.
Nutriband’s AVERSA™ abuse-deterrent technology can be utilized to incorporate aversive agents into transdermal patches to prevent the abuse, diversion, misuse, and accidental exposure of drugs with abuse potential including opioids and stimulants.
Nutriband’s abuse-deterrent transdermal technology consists of a proprietary aversive agent coating that employs taste aversion to deter the oral abuse of and accidental exposure to transdermal opioid and stimulant patch products.
The AVERSA™ abuse deterrent technology is protected by a broad international intellectual property portfolio with patents issued in 46 countries including the United States, Europe, Japan, Korea, Russia, China, Canada, Mexico, and Australia.
AVERSA Fentanyl has the potential to be the world’s first abuse-deterrent opioid patch designed to deter the abuse and misuse and reduce the risk of accidental exposure of transdermal fentanyl patches. AVERSA Fentanyl has the potential to reach peak annual US sales of
1 Health Advances Aversa Fentanyl market analysis report 2022
About AVERSA™ Abuse-Deterrent Transdermal Technology
Nutriband's AVERSA™ abuse-deterrent transdermal technology incorporates aversive agents into transdermal patches to prevent the abuse, diversion, misuse, and accidental exposure of drugs with abuse potential. The AVERSA™ abuse-deterrent technology has the potential to improve the safety profile of transdermal drugs susceptible to abuse, such as fentanyl, while making sure that these drugs remain accessible to those patients who really need them. The technology is covered by a broad intellectual property portfolio with patents granted in the United States, Europe, Japan, Korea, Russia, China, Canada, Mexico, and Australia.
About Nutriband Inc.
We are primarily engaged in the development of a portfolio of transdermal pharmaceutical products. Our lead product under development is an abuse-deterrent fentanyl patch incorporating our AVERSA™ abuse-deterrent technology. AVERSA™ technology can be incorporated into any transdermal patch to prevent the abuse, misuse, diversion, and accidental exposure of drugs with abuse potential.
The Company's website is www.nutriband.com. Any material contained in or derived from the Company's websites or any other website is not part of this press release.
Forward-Looking Statements
Certain statements contained in this press release, including, without limitation, statements containing the words "believes," "anticipates," "expects" and words of similar import, constitute "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. Such forward-looking statements involve both known and unknown risks and uncertainties. The Company's actual results may differ materially from those anticipated in its forward-looking statements as a result of a number of factors, including those including the Company's ability to develop its proposed abuse-deterrent fentanyl transdermal system and other proposed products, its ability to obtain patent protection for its abuse technology, its ability to obtain the necessary financing to develop products and conduct the necessary clinical testing, its ability to obtain Federal Food and Drug Administration approval to market any product it may develop in the United States and to obtain any other regulatory approval necessary to market any product in other countries, including countries in Europe, its ability to market any product it may develop, its ability to create, sustain, manage or forecast its growth; its ability to attract and retain key personnel; changes in the Company's business strategy or development plans; competition; business disruptions; adverse publicity and international, national and local general economic and market conditions and risks generally associated with an undercapitalized developing company, as well as the risks contained under "Risk Factors" and "Management's Discussion and Analysis of Financial Condition and Results of Operations" in the Company's Form S-1, Form 10-K for the year ended January 31, 2024, filed May 1, 2024, the Forms 10-Q’s filed subsequent to the Form 10-K in 2024, and the Company's other filings with the Securities and Exchange Commission. Except as required by applicable law, we undertake no obligation to revise or update any forward-looking statements to reflect any event or circumstance that may arise after the date hereof.
Contact Information:
Nutriband Inc.
Phone: 407-377-6695
Email: info@nutriband.com
FAQ
What is the potential market value for Nutriband's (NTRB) Aversa Fentanyl patch?
How many countries have granted patents for Nutriband's (NTRB) Aversa abuse-deterrent technology?
What is unique about Nutriband's (NTRB) Aversa Fentanyl patch?
How does Nutriband's (NTRB) Aversa abuse-deterrent technology work?
